Jefferies Group LLC lifted its stake in shares of Incyte Co. (NASDAQ:INCY) by 113.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 60,595 shares of the biopharmaceutical company’s stock after buying an additional 32,174 shares during the quarter. Jefferies Group LLC’s holdings in Incyte were worth $5,739,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. LMR Partners LLP purchased a new stake in shares of Incyte in the 3rd quarter worth about $394,000. Exane Derivatives purchased a new position in Incyte in the 4th quarter valued at about $669,000. Swiss National Bank lifted its holdings in Incyte by 3.0% in the 3rd quarter. Swiss National Bank now owns 641,700 shares of the biopharmaceutical company’s stock valued at $74,912,000 after purchasing an additional 18,700 shares in the last quarter. Prudential Financial Inc. lifted its holdings in Incyte by 0.6% in the 3rd quarter. Prudential Financial Inc. now owns 236,699 shares of the biopharmaceutical company’s stock valued at $27,633,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Columbus Circle Investors lifted its holdings in Incyte by 16.8% in the 3rd quarter. Columbus Circle Investors now owns 128,703 shares of the biopharmaceutical company’s stock valued at $15,025,000 after purchasing an additional 18,545 shares in the last quarter. Institutional investors and hedge funds own 93.58% of the company’s stock.
Several research analysts have recently weighed in on the stock. BidaskClub upgraded shares of Incyte from a “strong sell” rating to a “sell” rating in a report on Saturday, March 10th. ValuEngine raised shares of Incyte from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Raymond James Financial set a $159.00 price objective on shares of Incyte and gave the company a “buy” rating in a research report on Wednesday, February 28th. Oppenheimer set a $110.00 target price on Incyte and gave the company a “hold” rating in a research note on Tuesday, February 20th. Finally, Credit Suisse Group set a $145.00 target price on Incyte and gave the company a “buy” rating in a research note on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Incyte currently has an average rating of “Buy” and an average target price of $142.83.
Shares of Incyte Co. (INCY) traded up $1.34 during mid-day trading on Friday, hitting $90.03. The company had a trading volume of 1,977,841 shares, compared to its average volume of 1,519,872. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.01 and a quick ratio of 3.99. The company has a market cap of $18,784.43, a P/E ratio of -57.71 and a beta of 0.65. Incyte Co. has a 1-year low of $80.85 and a 1-year high of $149.27.
Incyte (NASDAQ:INCY) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.54. The business had revenue of $444.20 million for the quarter, compared to analysts’ expectations of $435.23 million. Incyte had a negative return on equity of 11.85% and a negative net margin of 20.38%. Incyte’s quarterly revenue was up 36.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.05 earnings per share. sell-side analysts predict that Incyte Co. will post -0.28 earnings per share for the current fiscal year.
In other news, EVP Reid M. Huber sold 1,958 shares of the company’s stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $85.55, for a total transaction of $167,506.90. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider David W. Gryska sold 6,760 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $98.87, for a total value of $668,361.20. Following the transaction, the insider now directly owns 20,752 shares in the company, valued at approximately $2,051,750.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,670 shares of company stock worth $1,489,181. 17.70% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Incyte Co. (INCY) Position Raised by Jefferies Group LLC” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://ledgergazette.com/2018/03/17/jefferies-group-llc-has-5-74-million-stake-in-incyte-co-incy.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.